Presentation is loading. Please wait.

Presentation is loading. Please wait.

Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study  Tiew-Hwa K Teng, PhD, Jasper.

Similar presentations


Presentation on theme: "Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study  Tiew-Hwa K Teng, PhD, Jasper."— Presentation transcript:

1 Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study  Tiew-Hwa K Teng, PhD, Jasper Tromp, MD, Wan Ting Tay, MAppStat, Inder Anand, MD, Wouter Ouwerkerk, PhD, Vijay Chopra, MD, Gurpreet S Wander, DM, Jonathan JL Yap, MBBS, Michael R MacDonald, MBChB, Chang Fen Xu, MBBS, Yvonne MF Chia, MBBS, Wataru Shimizu, MD, A Mark Richards, MD, Adriaan Voors, MD, Carolyn SP Lam, MBBS  The Lancet Global Health  Volume 6, Issue 9, Pages e1008-e1018 (September 2018) DOI: /S X(18) Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND 4.0 license Terms and Conditions

2 Figure 1 Regional variation in uptake
ACE=angiotensin-converting enzyme. ARB=angiotensin receptor blockers. MRA=mineralocorticoid receptor antagonists. The Lancet Global Health 2018 6, e1008-e1018DOI: ( /S X(18) ) Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND 4.0 license Terms and Conditions

3 Figure 2 Mean doses achieved by region
(A) Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. (B) β blockers. (C) Mineralocorticoid receptor antagonists. Achieved doses were calculated as a percentage of the dose recommended by guidelines. The Lancet Global Health 2018 6, e1008-e1018DOI: ( /S X(18) ) Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND 4.0 license Terms and Conditions

4 Figure 3 Association of doses achieved with 1-year composite outcome of all-cause deaths or hospitalisation for heart failure (A) Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. (B) β blockers. (C) Mineralocorticoid receptor antagonists. Achieved doses were calculated as a percentage of the dose recommended by guidelines. We used inverse probability weighting to adjust for indication bias. The Lancet Global Health 2018 6, e1008-e1018DOI: ( /S X(18) ) Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND 4.0 license Terms and Conditions


Download ppt "Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study  Tiew-Hwa K Teng, PhD, Jasper."

Similar presentations


Ads by Google